Pharmaceutisch Weekblad

, Volume 13, Issue 2, pp 58–69 | Cite as

Antiviral drugs

  • E. H. H. Wiltink
  • R. Janknegt


There are only a limited number of effective, non-toxic antiviral drugs for clinical use, whereas there is a great need for such drugs. Especially for the treatment of patients infected with the human immuno-deficiency virus (HIV) anti-HIV drugs are required. At the same time viral infections secondary to AIDS cannot yet be treated effectively. An increasing problem is the development of virus strains resistant to the available drugs. At this moment a great effort is made in the research for new antiviral drugs. In this article the available antiviral drugs are reviewed. Their antiviral properties, mechanism of action, clinical use, pharmacokinetic properties and side-effects are discussed. Some attention is paid to the future directions in the search for new anti-HIV drugs.


Antiviral agents Clinical trials Drug evaluation Pharmacokinetics Side-effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hirsch MS, Kaplan JC. Antiviral therapy. Sci Am 1987;256:66–75.Google Scholar
  2. 2.
    Wood MJ, Geddes AM. Antiviral therapy. Lancet 1987;2:1189–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986;32:383–424.PubMedGoogle Scholar
  4. 4.
    Mindel A. Comparative studies of inosine pranobex and acyclovir. Am J Med 1988;85(2A):7–9.CrossRefGoogle Scholar
  5. 5.
    Sandström EG, Kaplan JC. Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. Drugs 1987;34:372–90.PubMedGoogle Scholar
  6. 6.
    De Simone S, Tzantzoglou S, Vullo V, et al. Inosine pranobex and zidovudine metabolism. Lancet 1989;2:977.CrossRefGoogle Scholar
  7. 7.
    Pedersen C, Sandström E, Petersen GS, et al. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990;322:1757–63.PubMedGoogle Scholar
  8. 8.
    Dolin R. Amantadine and rimantadine. In: Peterson PK, Verhoef J, ed. Antimicrobial agents annual 3. Amsterdam: Elsevier Science Publishers, 1988:361–70.Google Scholar
  9. 9.
    Deeter RG, Khanderia U. Recent advances in antiviral therapy. Clin Pharm 1986;5:961–76.PubMedGoogle Scholar
  10. 10.
    Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes M, Soo W. Emergence and apparent transmission of rimantadine-resistent infuenza A virus in families. N Engl J Med 1989;321:1696–702.PubMedGoogle Scholar
  11. 11.
    Sears SD, Clements ML. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987;31:1470–3.PubMedGoogle Scholar
  12. 12.
    Santucci B, Picardo M, Cristaudo A. Contact dermatitis to tromantadine. Contact Dermatitis 1984;10:317–8.Google Scholar
  13. 13.
    Galasso GJ. Vidarabine. In: Peterson PK, Verhoef J, ed. Antimicrobial agents annual 3. Amsterdam: Elsevier Science Publishers, 1988:400–8.Google Scholar
  14. 14.
    Buchanan RA, Kinkel AW, Alford CA, Whitley RJ. Plasma level and urinary excretion of vidarabine after repeated dosing. Clin Pharm Ther 1980;27:690–6.Google Scholar
  15. 15.
    Balfour Jr HH. Acyclovir. In: Peterson PK, Verhoef J, ed. Antimicrobial agents annual 3. Amsterdam: Elsevier Science Publishers, 1988:345–60.Google Scholar
  16. 16.
    Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293–6.PubMedGoogle Scholar
  17. 17.
    Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:187–91.PubMedGoogle Scholar
  18. 18.
    Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1983;26:374–438.Google Scholar
  19. 19.
    Thin RN. Management of genital herpes simplex. Am J Med 1988;85(2A):3–6.Google Scholar
  20. 20.
    Mertz GJ, Eron L, Kaufman R, et al. Prolonged continuous versus intermittent oral acyclovir therapy treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988;85(2A):14–9.Google Scholar
  21. 21.
    Sköldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Lancet 1984;2:707–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Whitley RJ. Herpes simplex virus infections of the central nervous system. Am J Med 1988;85(2A):61–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Hermans PE, Cockerill III FR. Antiviral agents. Mayo Clin Proc 1987;62:1108–15.PubMedGoogle Scholar
  24. 24.
    Nahata MC. Clinical use of antiviral drugs. Drug Intell Clin Pharm 1987;21:399–405.PubMedGoogle Scholar
  25. 25.
    Petty BG, Whitley RJ, Liao S, et al. Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. J Antimicrob Chemother 1987;31:1317–22.Google Scholar
  26. 26.
    Fletcher CV, Balfour Jr HH. Evaluation of ganciclovir for cytomegalovirus disease. Drug Intell Clin Pharm 1989;23:5–12.Google Scholar
  27. 27.
    Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289–93.PubMedGoogle Scholar
  28. 28.
    Buhles Jr WG, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalo-virus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988;10(Suppl 3):495–506.Google Scholar
  29. 29.
    Ussery III FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988;95:640–8.PubMedGoogle Scholar
  30. 30.
    Oberg B. Antiviral effects of phosphonoformate. Pharmacol Ther 1983;19:387–415.CrossRefGoogle Scholar
  31. 31.
    Sjövall J, Karlsson A, Ogenstad S, Sandström E, Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988;44:65–73.PubMedGoogle Scholar
  32. 32.
    Walmsky SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate heseahydrate (foscarnet). J Infect Dis 1988;157:569–72.PubMedGoogle Scholar
  33. 33.
    Jacobson MA, O'Donnoll JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33:736–41.PubMedGoogle Scholar
  34. 34.
    Hall CB. Ribavirin. In: Peterson RK, Verhoef J, ed. Antimicrobial agents annual 3. Amsterdam: Elsevier Science Publishers, 1988:384–99.Google Scholar
  35. 35.
    Wald ER, Dashefsky B, Green M.In re ribavirin: a case of premature adjudication? J Pediatr 1988;112:154–8.PubMedGoogle Scholar
  36. 36.
    McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20–6.PubMedGoogle Scholar
  37. 37.
    Hartshorn KL, Hirsch MS. Interferons. In: Peterson PK, Verhoef J, ed. Antimicrobial agents annual 3. Amsterdam: Elsevier Science Publishers, 1988:371–83.Google Scholar
  38. 38.
    Balkwill FR. Interferons. Lancet 1989;1:1060–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Douglas RG. The common cold-relief at last? N Engl J Med 1986;314:114.PubMedGoogle Scholar
  40. 40.
    Sandström E. Antiviral therapy in human immuno-deficiency virus infection. Drugs 1989;38:417–50.PubMedGoogle Scholar
  41. 41.
    Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989;37:408–50.PubMedGoogle Scholar
  42. 42.
    Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988;2:1297–302.CrossRefPubMedGoogle Scholar
  43. 43.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4.PubMedGoogle Scholar
  44. 44.
    Lange JMA, Boucher CAB, Hollak CEM, et al. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med 1990;322:1375–7.PubMedGoogle Scholar
  45. 45.
    Schooley RT, Merigan TC, Gaut P, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1990;112:247–53.PubMedGoogle Scholar
  46. 46.
    Kahn JO, Allan JD, Hodges TL, et al. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1990;112:254–61.PubMedGoogle Scholar
  47. 47.
    Yarchoan R, Mitsuya H, Thomas RV, et al.In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989;245:412–5.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1991

Authors and Affiliations

  • E. H. H. Wiltink
    • 1
  • R. Janknegt
    • 2
  1. 1.Department of PharmacyUniversity Medical CentreAZ Amsterdamthe Netherlands
  2. 2.Department of Clinical PharmacyMaasland HospitalMB Sittardthe Netherlands

Personalised recommendations